Clinical Studies of a New Barbiturate (Nealbarbitone)

Publisher Website
Google Scholar
Abstract
In a small group of anxiety states treated as out-patients nealbarbitone is shown to be comparable in therapeutic activity to amylobarbitone sodium in the same dosage and to be therapeutically effective. The group as a whole although comparable in symptoms were of poorer outlook than a previously treated group and responded less well to treatment. No major toxic symptoms were observed and fewer new symptoms (possible side-effects) followed nealbarbitone than amylobarbitone. A trial with the drugs and pentobarbitone used as hypnotics by day, with observers present, and with EEG records of sleep showed that nealbarbitone is significantly less hypnotic than the other drugs. It is thus suggested that nealbarbitone is a therapeutically active sedative drug with low hypnotic activity. It seems desirable to repeat and attempt to confirm these results on a larger scale.